File: /home/govancoz/mail/new/1757142860.M297858P3543770.zacp120.webway.host,S=7104,W=7238
Return-Path: <asdt@sainet.or.jp>
Delivered-To: govancoz@zacp120.webway.host
Received: from zacp120.webway.host
by zacp120.webway.host with LMTP
id KD/FD0zfu2jaEjYA8rC0kQ
(envelope-from <asdt@sainet.or.jp>)
for <govancoz@zacp120.webway.host>; Sat, 06 Sep 2025 09:14:20 +0200
Return-path: <asdt@sainet.or.jp>
Envelope-to: candice@govan.co.za
Delivery-date: Sat, 06 Sep 2025 09:14:20 +0200
Received: from citron1.sainet.or.jp ([210.236.40.38]:53237)
by zacp120.webway.host with esmtp (Exim 4.98.2)
(envelope-from <asdt@sainet.or.jp>)
id 1uun7o-0000000ExY5-3ZIZ
for candice@govan.co.za;
Sat, 06 Sep 2025 09:14:20 +0200
Received: from ibis.sainet.or.jp (ibis [210.236.40.5])
by citron1.sainet.or.jp (Postfix) with ESMTP id D5538121002;
Sat, 6 Sep 2025 11:43:54 +0900 (JST)
Received: from ws-dip-gc02.diplomat.com.mt (c155-179.i01-7.onvol.net [212.56.155.179])
by ibis.sainet.or.jp (Postfix) with ESMTPA id 8B8F812004F;
Sat, 6 Sep 2025 11:43:38 +0900 (JST)
DKIM-Signature: v=1; a=rsa-sha256; c=relaxed/relaxed; d=sainet.or.jp;
s=default; t=1757126634;
bh=IlXQpdz6IB1Gn6wA9j4b/aRIwqywWkWHkkKvVdMS3mY=;
h=Subject:To:From:Date:Reply-To;
b=fB4zkdFNHMWXoYG854EGwSdqQa2IjjN8bqK1CnpQ9Y95ZxMrqCEALD4lzmLbdxOeQ
/5KgKAjkuLl/3HFnoyn9bER53U//xGl69Sa+R7Orsi0woTRae1InJ7EkwArcdOi0xF
VWtpxxI3lZelsBhQ1yBXPk36BVUqci3YSTT1zqgCR5ZXXbaJpr2/xXcqiRgsRsu5l1
0ySWKhyCexPSz0t0x+9TRTQ+3ezHRAL3ikll9jhg5nnmiM0KeeDtCXEltYRAbVvG6l
EkpKF5NT/Dx45UsbvTZASeYWZ9LwX19gbPYDW3peOCvzzjnic3F9aI7+XpFOpcI076
jj98RoyZd4t7Q==
Content-Type: multipart/alternative; boundary="===============0103954361=="
MIME-Version: 1.0
Subject: Proposal for Strategic Business Collaboration.
To: Recipients <asdt@sainet.or.jp>
From: "Dr. Shingo Iwamoto" <asdt@sainet.or.jp>
Date: Sat, 06 Sep 2025 04:43:21 +0200
Reply-To: drshingoiwamotopharm1@gmail.com
X-Spam-Status: No, score=1.8
X-Spam-Score: 18
X-Spam-Bar: +
X-Ham-Report: Spam detection software, running on the system "zacp120.webway.host",
has NOT identified this incoming email as spam. The original
message has been attached to this so you can view it or label
similar future email. If you have any questions, see
root\@localhost for details.
Content preview: Dear Esteemed Professional, I hope this message finds you
well. Nichi-Iko Pharmaceutical Co., Ltd., a leading pharmaceutical manufacturer
based in Japan, is currently seeking a qualified individual to [...]
Content analysis details: (1.8 points, 5.0 required)
pts rule name description
---- ---------------------- --------------------------------------------------
0.0 URIBL_BLOCKED ADMINISTRATOR NOTICE: The query to URIBL was blocked.
See
http://wiki.apache.org/spamassassin/DnsBlocklists#dnsbl-block
for more information.
[URI: sainet.or.jp]
-0.0 SPF_PASS SPF: sender matches SPF record
0.1 DKIM_SIGNED Message has a DKIM or DK signature, not necessarily valid
-0.1 DKIM_VALID_EF Message has a valid DKIM or DK signature from
envelope-from domain
-0.1 DKIM_VALID_AU Message has a valid DKIM or DK signature from author's
domain
-0.1 DKIM_VALID Message has at least one valid DKIM or DK signature
0.2 FREEMAIL_REPLYTO_END_DIGIT Reply-To freemail username ends in digit
[drshingoiwamotopharm1(at)gmail.com]
0.0 RCVD_IN_VALIDITY_RPBL_BLOCKED RBL: ADMINISTRATOR NOTICE: The query to
Validity was blocked. See
https://knowledge.validity.com/hc/en-us/articles/20961730681243
for more information.
[210.236.40.38 listed in bl.score.senderscore.com]
0.0 RCVD_IN_VALIDITY_SAFE_BLOCKED RBL: ADMINISTRATOR NOTICE: The query to
Validity was blocked. See
https://knowledge.validity.com/hc/en-us/articles/20961730681243
for more information.
[210.236.40.38 listed in sa-accredit.habeas.com]
0.0 RCVD_IN_VALIDITY_CERTIFIED_BLOCKED RBL: ADMINISTRATOR NOTICE: The
query to Validity was blocked. See
https://knowledge.validity.com/hc/en-us/articles/20961730681243
for more information.
[210.236.40.38 listed in sa-trusted.bondedsender.org]
0.0 HTML_MESSAGE BODY: HTML included in message
1.8 FREEMAIL_FORGED_REPLYTO Freemail in Reply-To, but not From
X-Spam-Flag: NO
You will not see this in a MIME-aware mail reader.
--===============0103954361==
Content-Type: text/plain; charset="iso-8859-1"
MIME-Version: 1.0
Content-Transfer-Encoding: quoted-printable
Content-Description: Mail message body
Dear Esteemed Professional,
I hope this message finds you well.
Nichi-Iko Pharmaceutical Co., Ltd., a leading pharmaceutical manufacturer =
based in Japan, is currently seeking a qualified individual to serve as our=
official representative in South Africa. This role involves managing miner=
al procurement and overseeing the establishment of our annex office in Sout=
h Africa under a five-year contractual agreement.
This is a strategic opportunity to represent a respected global brand and =
play a key role in expanding our international presence. We are offering a =
competitive compensation package along with decision-making autonomy.
If you are interested in learning more, kindly respond to this message for=
further details.
Warm regards,
Dr. Shingo Iwamoto
President & CEO
Nichi-Iko Pharmaceutical Co., Ltd.
5-4 Nihonbashi-Honcho 1-chome, Chuo-ku, Tokyo, Japan
--===============0103954361==
Content-Type: text/html; charset="iso-8859-1"
MIME-Version: 1.0
Content-Transfer-Encoding: quoted-printable
Content-Description: Mail message body
<HTML><head><meta http-equiv=3D"Content-Type" content=3D"text/html; charset=
=3Diso-8859-1"/></head><BODY><P>Dear Esteemed Professional,</P>
<P>I hope this message finds you well.</P>
<P>Nichi-Iko Pharmaceutical Co., Ltd., a leading pharmaceutical manufacture=
r based in Japan, is currently seeking a qualified individual to serve as o=
ur official representative in South Africa. This role involves managing min=
eral procurement and overseeing the establishment of our annex office in So=
uth Africa under a five-year contractual agreement.</P>
<P>This is a strategic opportunity to represent a respected global brand an=
d play a key role in expanding our international presence. We are offering =
a competitive compensation package along with decision-making autonomy.</P>
<P>If you are interested in learning more, kindly respond to this message f=
or further details.</P>
<P>Warm regards,<BR>Dr. Shingo Iwamoto<BR>President & CEO<BR>Nichi-Iko =
Pharmaceutical Co., Ltd.<BR>5-4 Nihonbashi-Honcho 1-chome, Chuo-ku, Tokyo, =
Japan</P></BODY></HTML>
--===============0103954361==--